This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

About

About

EfficacyMOAMist MomentsSafety & Dosing

Safety &
Dosing

SafetyDosingPrescribing

Prescribing

Access & SavingsZavzpret OneSourcePractice Resources

Practice Resources

EventsMaterialsVideosPA Resources
Prescribing InformationPatient Information Instructions for UseIndication Press Release
For the acute treatment of migraine with or without aura in adultsFor the acute treatment of migraine with or without aura in adultsThe first and only CGRP receptor antagonist
nasal spray1,2The first and only CGRP receptor antagonist
nasal spray1,2The first and only CGRP receptor antagonist
nasal sprayIndications & DosingAdultsChildren AdultsChildren 
Explore the phase 3 pivotal trial results1
 See efficacy Loading
One spray in one nostril for rapid absorption1,3
 See dosing Loading
Access and savings
information for ZAVZPRET
 See prescribing Loading
Connect with a  ZAVZPRET representative

Have a question? A product representative can help.

 Request a representative LoadingReferences:Zavzpret. Package insert. Pfizer Inc.Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(13):209-217. doi:10.1016/S1474-4422(22)00517-8Bitter C, Sutter-Zimmerman K, Surber C. Nasal drug delivery in humans. Curr Probl Dermatol. 2011;40:20-35. doi:10.1159/000321044

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-ZAZ-USA-0093
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367


​​​​​​​
INDICATION

ZAVZPRETTM (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Important Safety Information Contraindications: Hypersensitivity to ZAVZPRET or any of its components.

Warnings and Precautions: Hypersensitivity reactions, including facial swelling and urticaria, have occurred with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.

Adverse Reactions: Most common adverse reactions (occurring in ≥2% of patients treated with ZAVZPRET and greater than placebo) for ZAVZPRET vs placebo were taste disorders including dysgeusia and ageusia (18% vs 4%), nausea (4% vs 1%), nasal discomfort (3% vs 1%), and vomiting (2% vs 1%).

Drug Interactions: Avoid use with drugs that inhibit or induce OATP1B3 or NTCP transporters. Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.

Use in Specific Populations: Hepatic Impairment: Avoid use in patients with severe hepatic impairment. Renal impairment: Avoid use of ZAVZPRET in patients with creatinine clearance (CLcr) less than 30 mL/min.

Please click here for full Prescribing Information.IndicationZAVZPRET™️ (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Please see Full Prescribing Information.